Qurient Co., Ltd. Announces Significant Advances in Cancer Treatment
Seongnam, South Korea – Qurient Co., Ltd. (KRX: 115180), a clinical-stage biotechnology company, has published compelling findings in Science Advances, demonstrating the potential of combining CDK7 inhibitors with topoisomerase I (TOP1) inhibitors in cancer therapeutics.
Key Highlights:
-
Enhanced Antitumor Activity: The study reports that Qurient’s selective CDK7 inhibitor, Q901 (mocaciclib), significantly boosts the effectiveness of TOP1 inhibitor-based antibody-drug conjugates (TOP1i-ADCs).
-
Mechanistic Insights: Q901 impairs transcription programs driven by MYC and E2F, which leads to reduced expression of important homologous recombination repair (HRR) genes. This results in prolonged retention of TOP1-DNA protein crosslinks (TOP1-DPCs), enhancing tumor-cell sensitivity.
-
Quotes from Leadership: “This publication elucidates the complementary molecular mechanism between CDK7 and TOP1 inhibition,” stated Kiyean Nam, Ph.D., CEO of Qurient. He emphasizes the focus on developing next-generation dual-payload ADCs.
Research Findings:
-
Selective CDK7 Inhibition: Q901 shows high selectivity, forming a covalent bond with CDK7.
-
DNA Damage Repair Suppression: It disrupts oncogenic transcription, reducing vital DNA repair gene expression.
-
TOP1-DPC Persistence: CDK7 inhibition limits RNA polymerase II elongation, resulting in longer persistence of TOP1-DPCs and increased DNA damage.
-
Improved Efficacy: In preclinical trials, Q901 significantly enhanced antitumor activity with leading ADCs like trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG).
Future Implications
The findings establish a robust rationale for combining Q901 with existing TOP1i-ADCs, paving the way for developing dual-payload ADCs that integrate both CDK7 and TOP1 inhibitors, aimed at improving cancer treatment outcomes.
About Qurient Co., Ltd.
Qurient Co., Ltd. specializes in developing innovative cancer therapeutics, including a pipeline of small-molecule drugs and next-generation ADCs. For more information, visit www.qurient.com.
Contact:
Qurient Co., Ltd.
Investor & Media Relations: Noah Choi
Phone: +(82)-31-8060-1600
Email: media@qurient.com
